이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

혈소판감소증이 있는 골수섬유증 환자를 위한 파크리티닙 (PACRIMYEL)

혈소판감소증이 있는 골수섬유증 환자의 골수 섬유화 감소를 위한 파크리티닙; 다기관, 개방형, 단일 군, 2상 탐색 연구

We hypothesize that pacritinib leads to modification of the myelofibrosis (MF) disease phenotype, especially related to BM fibrosis and cytopenias; due potentially to its dual effect as an inhibitor of the JAK and NFκB pathways, through its targets JAK2 and IRAK1 respectively, leading to a decrease of inflammatory cytokines and/or effects on stem/progenitor populations restoring hematopoiesis New evidence suggests that blocking simultaneously the JAK/STAT and NF-κB pathways might have a beneficial effect on aspects that only inhibition of the JAK pathway cannot achieve: partial recovery of BM histology and

PACRIMYEL is a multicenter, open-label, single arm, phase II, exploratory study including patients with MF and platelet count between 50 - 120 x 109/L. Clinic visits will occur on weeks 4, 8, 12, 24, 36 and 52 during the first year and every 12 weeks during the second year of the treatment, and pacritinib will be dispensed at every visit to the clinic.

Bone fibrosis will be assessed by biopsy and MRI imaging [mDixon Quant "(Philips), IDEAL IQ (General Electric) or qDixon (Siemens)] on weeks 24 and 52 after the first dose of study treatment. Splenomegaly and SVR (Splenic Volume Reduction) will be assessed by physical exam and MRI imaging on weeks 24 and 52 after the first dose of study treatment if splenomegaly at diagnosis. Same MRI to evaluate BM imaging will be used to measure spleen volume. Additionally, spleen size will be assessed by physical exam during the routine clinic visits. All patients should complete all efficacy assessments through Week 52, including patients who stop study treatment or have protocol-defined progressive disease prior to Week 24 and 52, unless the patient withdraws consent or dies. For patients who discontinue treatment before disease assessments on week 24 and week 52 for other reasons different than protocol-based progression of the disease (i.e. toxicity), and with no recent disease / fibrosis assessment (last BM biopsy > 12 weeks), disease and fibrosis assessments will be performed by the end of treatment visit. The trial includes the assessment of safety (AEs, comorbidities) throughout the study period at every visit.

Patient-reported symptoms through MPN-SAF TSS 2.0 will be collected screening, baseline (C1D1), and on Week 12, Week 24, Week 36, Week 52 and in 12-weeks intervals during the second year. Blood samples for translational research will be collected at screening and at week 24 for determination of cytokines.

연구 개요

상태

모병

개입 / 치료

연구 유형

중재적

등록 (추정된)

30

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: A Responsible Person Designated by the sponsor, M.D., PhD.
  • 전화번호: 0034934344412
  • 이메일: investigacio@mfar.net

연구 연락처 백업

연구 장소

    • Barcelona
      • Barcelona, Barcelona, 스페인, 08035
        • 모병
        • Hospital Universitario Vall d´Hebron
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
      • Barcelona, Barcelona, 스페인, 08036
        • 모병
        • Hospital Clinic de Barcelona
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
      • Barcelona, Barcelona, 스페인, 08003
        • 모병
        • Hospital del Mar Barcelona
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
    • Cádiz
      • Jerez de la Frontera, Cádiz, 스페인, 11407
        • 모병
        • Hospital Universitario de Jerez
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
    • Madrid
      • Madrid, Madrid, 스페인, 28034
        • 모병
        • Hospital Universitario Ramon y Cajal
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
      • Madrid, Madrid, 스페인, 28041
        • 모병
        • Hospital Universitario 12 de Octubre
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
      • Madrid, Madrid, 스페인, 28007
        • 모병
        • Hospital General Universitario Gregorio Marañon
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
      • Madrid, Madrid, 스페인, 28040
        • 모병
        • Fundación Jimenez Díaz
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
    • Murcia
      • Murcia, Murcia, 스페인, 30008
        • 모병
        • Hospital General Universitario Morales Meseguer
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
    • Salamanca
      • Salamanca, Salamanca, 스페인, 37007
        • 모병
        • Hospital Universitario de Salamanca
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
    • Valencia
      • Valencia, Valencia, 스페인, 46014
        • 모병
        • Hospital General Universitario de Valencia
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
      • Valencia, Valencia, 스페인, 46017
        • 아직 모집하지 않음
        • Hospital Universitario Doctor Peset
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.
      • Valencia, Valencia, 스페인, 46010
        • 모병
        • Hospital Clínico Universitario Valencia
        • 연락하다:
          • A responsible person Designated by the Sponsor
          • 전화번호: 0034934344412
          • 이메일: investigacion@mfar.net
        • 수석 연구원:
          • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D.

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Signed written and voluntary informed consent.

  2. Age ≥18 years

  3. Patients with a confirmed diagnosis of myelofibrosis, either primary myelofibrosis (PMF) or post polycythemia vera (PPV-MF) or post essential thrombocythemia (PET-MF).

  4. Patients with thrombocytopenia, delimited by platelets counts between 50 - 120 x 109/L.

  5. Patients who require JAK-2 inhibitor therapy in the opinion of the investigator and are eligible to start treatment with pacritinib either in the first line (JAK2 inhibitor-naive) or in second line setting (after no response or loss of response or intolerance to one prior JAK2 inhibitor ).

    Note: patients should have recovered to grade ≤ 1 from any toxicity from previous treatment.

  6. Have a Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 - 2.

  7. Have a dynamic international prognostic scoring system (DIPSS) Intermediate-1, Intermediate-2, or High risk.

  8. Peripheral blasts count < 5% and absolute neutrophil count (ANC) of ≥500/μL.

  9. Adequate liver and renal function, defined by:

    1. liver transaminases, including alanine aminotransferase (ALT or GOT) and aspartate aminotransferase (AST or GOT) ≤ 3 x upper limit normal (ULN). AST/ALT ≤5 × ULN if transaminase elevation is related to MF.
    2. Total bilirubin and/or direct bilirubin ≤ 4 x ULN.
    3. Estimated glomerular filtration rate (eGFR) > 30 mL/min.
  10. Adequate coagulation defined by prothrombin time/international normalized ratio and partial thromboplastin time ≤ 1.5 × ULN.

  11. If fertile, willing to use effective birth control methods during the study and up to 30 days after the last dose of pacritinib.

  12. Willing to undergo and able to tolerate frequent MRI during the study and BM biopsy

  13. Able to understand and willing to complete symptom assessments.

Exclusion Criteria:

  1. Life expectancy <6 months.
  2. Splenic irradiation within the last 6 months.
  3. Previously treated with pacritinib.
  4. Concurrent enrollment in another interventional trial.
  5. Treatment with an experimental therapy within 28 days prior to the first dose of study treatment.
  6. Systemic treatment with a strong CYP3A4 inhibitor or inducer and the treatment cannot be either discontinued or switched to a different medication within 5 half-lifes prior to study entry.
  7. Severe (Child-Pugh C) liver impairment.
  8. Significant recent bleeding history defined as NCI CTCAE grade ≥2 within 3 months prior to first dose of study treatment, or with active bleeding, unless precipitated by an inciting event (e.g., surgery, trauma, or injury).
  9. Conditions or medications that increase the risk of bleeding, except for aspirin (dosages of ≤100 mg per day). Patients treated with "direct-acting oral anticoagulants (DOACs), could be considered for inclusion (may be consulted with the Sponsor, GEMFIN).
  10. Any history of CTCAE grade ≥2 dysrhythmias or non-dysrhythmia cardiac conditions within 6 months prior to the first dose of study treatment. Patients with non-dysrhythmia or non-QTc grade 2 cardiovascular conditions , may be considered for inclusion, if stable , asymptomatic and unlikely to affect patient safety.
  11. QT corrected by the Fridericia method (QTcF) prolongation >480 ms or other factors that increase the risk for QTcF interval prolongation (e.g., heart failure, hypokalemia or history of long QT interval syndrome).
  12. New York Heart Association Class II, III, or IV congestive heart failure.
  13. Active or uncontrolled inflammatory or chronic functional bowel disorder such as Crohn's disease, inflammatory bowel disease, chronic diarrhea or constipation
  14. Other malignancy within 3 years prior to treatment Day 1, other than curatively treated basal cell or squamous cell skin or corneal cancer; curatively treated carcinoma in situ of the cervix. The exception is if patients have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy.
  15. Known seropositivity for human immunodeficiency virus. Known active hepatitis B, or C virus infection.
  16. Women who are pregnant or lactating
  17. Uncontrolled intercurrent illness, including, but not limited to, ongoing active infection, psychiatric illness, or social situation that, in the judgment of the treating physician, would limit compliance with study requirements.
  18. Any active GI or metabolic condition that could interfere with absorption of oral medication.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: PACRIMYEL

Pacritinib administed 200 mg twice a day (BID)

All patients enrolled will receive pacritinib 200 mg twice a day (BID). The maximum daily dose will be 400 mg of pacritinib. Pacritinib dose may be reduced by one level to 100 mg BID (200 mg total daily dose), or by two levels to 100 mg once daily (QD) for management of AEs. The treatment will be continued until progressive disease, unacceptable toxic effects, the patient no longer derives benefit from treatment, patients consent withdrawal or death, whichever occurs first.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Decrease in reticulin fibrosis in bone marrow (BM)
기간: from baseline to week 52 after first dose of study treatment

Measured in BM biopsy. Percentage of patients who experience a decrease of ≥1 grade in reticulin fibrosis from baseline to week 52. Definition of BM fibrosis grade will follow the European consensus that ranges from 0 (scattered, less fibrotic) to 3 (difuse and dense reticulin, more fibrotic). Patients will be classified as improvement (fibrosis decrease ≥1 grade), no change, or worsening (fibrosis increase > 1 grade).

from baseline to week 52 after first dose of study treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Improvement in BM fat fraction (FF)
기간: from baseline to week 52 after first dose of study treatment

measured by quantitative quantitative Dixon Quant MRI or equivalent. Changes in the bone marrow associated with MF, such as replacement of the bone marrow fat by fibrosis or elevated numbers of hematopoietic cells, reduce the abundance of fat. Here we will report the percentage of patient who had an improvement in the FF (increase from baseline at week 52).

from baseline to week 52 after first dose of study treatment
red blood cell (RBC) transfusion independence
기간: from baseline to week 24 and week 52 after first dose of study treatment

Percentage of patients who achieved no need of RBC transfusions during at least 12 week.

RBC transfusion independence will be reported in subgroup of patients with the changes in the Bone Marrow (by MRI and/or BM biopsy) over the first 24 and 52 weeks of treatment.

from baseline to week 24 and week 52 after first dose of study treatment
Improvement in hemoglobin level
기간: from baseline to week 24 and week 52 after first dose of study treatment

Percentage of patients who improve their hemoglobin levels without transfusion. Improvement was defined as a ≥ 1.5 g/dL increase in hemoglobin from baseline.

Changes in hemoglobin level without transfusion will be reported in subgroup of patients with the changes in the Bone Marrow (by MRI and/or BM biopsy) over the first 24 and 52 weeks of treatment.

from baseline to week 24 and week 52 after first dose of study treatment
Improvement in platelet counts
기간: from baseline to week 24 and week 52 after first dose of study treatment

increase of platelet count (without transfusions) in comparison to baseline of above 75 x 109/L (if platelet count was between 50 - 75 109/L at baseline) or above 100 x 109/L (if platelet count was between 75 - 100 x 109/L at baseline). Alternatively, the proportion of patients who increase platelet counts ≥25% above baseline will be measured.

from baseline to week 24 and week 52 after first dose of study treatment
Myeloproliferative neoplasms (MPN) driver-gen Variant Allele Frequency (VAF)
기간: Baseline and at Week 24 and Week 52 after the first dose of study treatment

JAK2, CALR, and MPL genes are drivers of myelofibrosis. Their VAF could be quantified in peripheral blood or bone marrow and its circulating levels are usually correlated with the course of the disease. We aim to find the percentage of patients who reduced their VAF at week 24 and 52.

Baseline and at Week 24 and Week 52 after the first dose of study treatment
Cummulative dose
기간: Throughout the study period, up to approximately 2 years

the sum of all doses of pacritinib taken from the start of study treatment, taken into consideration interruptions and reductions.

Throughout the study period, up to approximately 2 years
Actual dose of pacritinib
기간: Throughout the study period, up to approximately 2 years

defined as the real average daily dose administered. For its calculation, the cumulative dose will be divided by the duration of the treatment, considering also the interruption periods.

Throughout the study period, up to approximately 2 years
Relative dose intensity of pacritinib
기간: Throughout the study period, up to approximately 2 years

Defined as the percentage of the planned dose that has been actually administered. Calculated dividing actual dose by planned dose per day.

Throughout the study period, up to approximately 2 years
Frequency of treatment-related adverse events
기간: Throughout the study period, up to approximately 2 years

number of patients who experience a treatment-related adverse event. Events will be classified and graded according to National Cancer Institute (NCI) Common Terminology Criteria (CTCAE) version 5.0

Throughout the study period, up to approximately 2 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 의자: Francisca Ferrer Marín, M.D.; Ph.D., Fundación Jimenez Díaz

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 4월 15일

기본 완료 (추정된)

2027년 12월 1일

연구 완료 (추정된)

2028년 6월 1일

연구 등록 날짜

최초 제출

2026년 2월 2일

QC 기준을 충족하는 최초 제출

2026년 2월 2일

처음 게시됨 (실제)

2026년 2월 6일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다